Literature DB >> 19820029

Acute hyperinsulinemia differentially regulates interstitial and circulating adiponectin oligomeric pattern in lean and insulin-resistant, obese individuals.

Giuseppe Murdolo1, Ann Hammarstedt, Martin Schmelz, Per-Anders Jansson, Ulf Smith.   

Abstract

CONTEXT: Hyperinsulinemia emerges as a negative modulator of the circulating high-molecular-weight adiponectin multimers.
OBJECTIVES: Here we asked whether, in vivo, acute hyperinsulinemia regulates adiponectin formation and oligomeric complex distribution at the transcriptional or posttranslational level.
DESIGN: Nine lean and nine uncomplicated obese males were studied in the postabsorptive state and during a euglycemic-hyperinsulinemic clamp combined with the microdialysis technique. Subcutaneous abdominal adipose tissue biopsies and interstitial and serum samples were taken at baseline and after the hyperinsulinemia. Adiponectin complexes were characterized by nonheating/nonreducing SDS-PAGE.
RESULTS: At baseline, serum and interstitial total adiponectin levels were lower (P < 0.01) in obese than in lean subjects primarily due to a reduction of the high-molecular-weight isoforms. After hyperinsulinemia, serum and interstitial total adiponectin was reduced in both groups. The degree of adiponectin reduction was more prominent in interstitial fluid than in serum. Lean individuals showed an equal suppression of the high-, low-, and middle-molecular-weight adiponectin complexes both in serum and in situ (P < 0.01 vs. basal). In obese subjects, despite the lower interstitial adiponectin subfractions, insulin challenge reduced significantly the circulating middle-molecular-weight forms only. At the mRNA level, adiponectin and its receptors 1 and 2, as well as the abundance of the endoplasmic reticulum chaperone proteins ERp44 and Epsilonro1-Lalpha were similar within the groups, before and after the clamp.
CONCLUSIONS: In human obesity, the impaired adiponectin oligomeric pattern in the circulation is mimicked at the tissue level, and hyperinsulinemia may differentially affect the compartmental distribution of the adiponectin complexes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19820029     DOI: 10.1210/jc.2009-0431

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Regulation of adiponectin production by insulin: interactions with tumor necrosis factor-α and interleukin-6.

Authors:  Tahar Hajri; Huan Tao; Julia Wattacheril; Pamela Marks-Shulman; Naji N Abumrad
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-11-09       Impact factor: 4.310

Review 2.  Metabolically healthy obesity: facts and fantasies.

Authors:  Gordon I Smith; Bettina Mittendorfer; Samuel Klein
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

3.  Inflammatory adipokines, high molecular weight adiponectin, and insulin resistance: a population-based survey in prepubertal schoolchildren.

Authors:  Giuseppe Murdolo; Bettina Nowotny; Federica Celi; Miranda Donati; Vittorio Bini; Francesco Papi; Gabi Gornitzka; Serena Castellani; Michael Roden; Adriano Falorni; Christian Herder; Alberto Falorni
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

4.  Adiponectin, chemerin, cytokines, and dipeptidyl peptidase 4 are released from human adipose tissue in a depot-dependent manner: an in vitro system including human serum albumin.

Authors:  Henrik Svensson; Birgitta Odén; Staffan Edén; Malin Lönn
Journal:  BMC Endocr Disord       Date:  2014-01-22       Impact factor: 2.763

Review 5.  Altered transendothelial transport of hormones as a contributor to diabetes.

Authors:  Nanyoung Yoon; Thanh Q Dang; Helen Chasiotis; Scott P Kelly; Gary Sweeney
Journal:  Diabetes Metab J       Date:  2014-04       Impact factor: 5.376

6.  The autophagy protein Becn1 improves insulin sensitivity by promoting adiponectin secretion via exocyst binding.

Authors:  Kenta Kuramoto; Yoon-Jin Kim; Jung Hwa Hong; Congcong He
Journal:  Cell Rep       Date:  2021-05-25       Impact factor: 9.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.